News & Events zu Joint Corp (JYNT)JYNTJoint Corp

The Joint Increases Stock Repurchase Authorization by $5 Million

The company said, "Our success with our clinic refranchising efforts has positioned The Joint as a pure-play franchisor model, which, combined with RD territory buybacks already completed this year, is helping to drive margin improvement, profitability and cash flow. With our strong balance sheet and improving cash generation from continuing operations, we have the financial flexibility to continue to execute simultaneously on our growth strategies, RD territory buybacks and continued stock repurchase capital allocation priorities. Our additional $5 million stock repurchase authorization reflects our confidence that our asset-light franchise model and initiatives to reignite growth will help create long-term value for our stockholders."

The Joint Corp. Reports Q3 Revenue of $13.55M

Reports Q3 revenue $13.55M, consensus $14.85M. System-wide sales were $123.3M, a 3.1% decrease compared to the third quarter of 2025. "Our third quarter results reflect growth in our active membership count as well as in the lifetime value per active member," said President and Chief Executive Officer of The Joint Corp., Sanjiv Razdan. "By leaning into our value proposition, especially with our newer flexible membership options, we are driving more members to stay with us longer. Primarily reflecting the ongoing macroeconomic challenges, growth in these metrics is partially offset by lower average patient spend per month and fewer new patients, which is continuing to impact our comps. We believe our ability to grow our active membership count and our stronger new clinic performance is strengthening our foundation for future growth."

Company Expects System-wide Sales Between $519 Million and $552 Million

The company said, "System-wide sales are expected to be between $519 million and $552 million. System-wide comp sales for clinics open 13 months or more are expected to be in the range of (3)% to 3%."